On Friday, Acumen Pharmaceuticals Inc (NASDAQ: ABOS) opened higher 12.50% from the last session, before settling in for the closing price of $1.36. Price fluctuations for ABOS have ranged from $0.86 to $3.36 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -54.87% annually for the last half of the decade. Company’s average yearly earnings per share was noted -26.65% at the time writing. With a float of $46.91 million, this company’s outstanding shares have now reached $60.57 million.
Acumen Pharmaceuticals Inc (ABOS) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Acumen Pharmaceuticals Inc is 22.56%, while institutional ownership is 54.12%. The most recent insider transaction that took place on Jan 23 ’25, was worth 49,633. In this transaction CFO & Chief Business Officer of this company sold 28,902 shares at a rate of $1.72, taking the stock ownership to the 231,744 shares. Before that another transaction happened on Jan 21 ’25, when Company’s CFO & Chief Business Officer sold 4,364 for $1.60, making the entire transaction worth $6,986. This insider now owns 260,646 shares in total.
Acumen Pharmaceuticals Inc (ABOS) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.5 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.3) by -0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.55 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -26.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.51% during the next five years compared to -54.87% drop over the previous five years of trading.
Acumen Pharmaceuticals Inc (NASDAQ: ABOS) Trading Performance Indicators
Check out the current performance indicators for Acumen Pharmaceuticals Inc (ABOS). In the past quarter, the stock posted a quick ratio of 5.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.27, a number that is poised to hit -0.54 in the next quarter and is forecasted to reach -1.65 in one year’s time.
Technical Analysis of Acumen Pharmaceuticals Inc (ABOS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.27 million. That was inferior than the volume of 0.33 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 69.57%.
During the past 100 days, Acumen Pharmaceuticals Inc’s (ABOS) raw stochastic average was set at 72.97%, which indicates a significant decrease from 82.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1086 in the past 14 days, which was higher than the 0.0950 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3392, while its 200-day Moving Average is $1.4843. However, in the short run, Acumen Pharmaceuticals Inc’s stock first resistance to watch stands at $1.6333. Second resistance stands at $1.7367. The third major resistance level sits at $1.8733. If the price goes on to break the first support level at $1.3933, it is likely to go to the next support level at $1.2567. Assuming the price breaks the second support level, the third support level stands at $1.1533.
Acumen Pharmaceuticals Inc (NASDAQ: ABOS) Key Stats
There are currently 60,573K shares outstanding in the company with a market cap of 92.67 million. Presently, the company’s annual sales total 0 K according to its annual income of -102,330 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -40,950 K.
